Catalog No.
Product Name
Application
Product Information
Citations
-
P2YR Activator
Sp-UTP-α-S (Uridine 5'-O-1-thiotri-phosphate) functions as an activator of P2Y2 and P2Y4 receptors. This compound is particularly useful in cancer research, where it can help elucidate the roles of purinergic signaling in tumor biology. By activating these receptors, Sp-UTP-α-S may contribute to studies related to cell proliferation, migration, and signaling pathways associated with cancer progression. -
P2Y2 Receptor Agonist
PSB-1114 tetrasodium is a potent agonist of the P2Y2 receptor, exhibiting an EC50 of 134 nM and demonstrating significant enzymatic stability. This compound is highly selective, showing over 50-fold selectivity against the P2Y4 and P2Y6 receptors, with EC50 values of 9.3 μM and 7.0 μM, respectively. PSB-1114 tetrasodium is valuable for research applications focusing on P2Y2 receptor-mediated signaling pathways and related physiological processes. -
P2Y12 Receptor Antagonist
MRS2395 is a potent antagonist of the P2Y12 receptor, a key regulator of platelet activity. It effectively inhibits ADP-induced platelet activation with a half-maximal inhibitory concentration (Ki) of 3.6 μM and suppresses cAMP production in rat platelets in the presence of PGE1 with an IC50 of 7 µM. Additionally, MRS2395 promotes the release of dense granules from platelets in response to TRAP-6, making it a valuable tool for research into platelet function and thrombotic disorders. -
P2Y6 Receptor Agonist
5-OMe-UDP, a potent P2Y6 receptor agonist with an EC50 of 0.08 μM, activates the P2Y6 receptor by binding and initiating intracellular signaling cascades. This activation results in increased intracellular calcium ion concentration, influencing various cellular functions. The presence of methoxy groups in 5-OMe-UDP enhances its selectivity and activity, making it a valuable tool for investigating pathologies associated with P2Y6 receptor function, including diabetes, inflammatory bowel disease, and Alzheimer's disease. -
P2Y2/P2Y4 Agonist
Uridine-5'-O-(3-thiotriphosphate) (UTPγS) is a stable analogue of Uridine triphosphate (UTP) that acts as a potent agonist for the P2Y2 and P2Y4 receptors. It demonstrates significant biological activity by stimulating inositol phosphate formation in human 1321N1 astrocytoma cells that express the phospholipase C-coupled human P2U-purinoceptor, with an EC50 value of 240 nM. This compound is valuable for research applications focused on purinergic signaling and receptor pharmacology. -
P2Y1R Antagonist
Desmodilactone is an allosteric antagonist of the P2Y1 receptor. It exhibits significant potential in modulating platelet activation and aggregation, thereby contributing to research on thrombosis and related cardiovascular conditions. This compound can be utilized in studies aimed at understanding P2Y1 signaling pathways and developing targeted therapies for thrombotic diseases. -
P2Y12 Antagonist
ACT-281959 is an orally bioavailable prodrug of Selatogrel, functioning as a P2Y12 receptor antagonist. This reagent effectively inhibits platelet aggregation, making it a valuable tool for investigating cardiovascular diseases and related pathophysiological mechanisms. Its utility in research can aid in the development of therapeutic strategies targeting thrombotic disorders. -
P2Y1 Antagonist
P2Y1 antagonist 1 is a highly effective antagonist of the P2Y1 receptor, exhibiting IC50 values of 1.1 nM in the FLIPR assay and 0.24 μM in the hPA assay. This compound is crucial for advancing antiplatelet research, providing insights into the modulation of platelet activation and implications for cardiovascular therapeutics. Its potent inhibitory action makes it a valuable tool for studying P2Y1-related biological pathways. -
P2Y1 Antagonist
Adenosine 3'-phosphate 5'-phosphosulfate is a selective antagonist of the P2Y1 receptor, effectively inhibiting ADP-induced platelet aggregation without affecting P2Y2, P2Y4, or P2Y6 receptors. This compound disrupts the ability of ADP to induce shape change and elevate intracellular Ca2+ levels in platelets while not influencing ADP's inhibition of adenylate cyclase. In addition to its antagonistic properties, Adenosine 3'-phosphate 5'-phosphosulfate serves as a co-substrate for glycan sulfonation, and can be utilized in Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays for sulfonate group transfer. -
P2Y2/P2Y4 Activator
Ap4C tetrasodium is an activator of P2Y2 and P2Y4 receptors, functioning as a signaling molecule through its interaction with these purinergic receptors. It induces platelet aggregation and mediates various cellular responses, making it a key reagent in the study of inflammation and blood coagulation pathways. This compound is valuable for research applications focusing on the pharmacology of platelet function and related vascular processes. -
P2Y Receptor Antagonist
P2Y12 antagonist 1 is a P2Y12 receptor antagonist, exhibiting a Ki of 3.13 μM. This compound effectively inhibits platelet aggregation, making it a promising candidate for antithrombotic applications in cardiovascular research. Its role in modulating P2Y12 receptor activity highlights its potential for investigating platelet function and thrombus formation. -
P2Y1/13 Receptor Antagonist
MRS2603 is a pyridoxal derivative that acts as a potent antagonist of the P2Y1 and P2Y13 receptors. This compound exhibits significant biological activity by inhibiting the signaling pathways mediated by these purinergic receptors. MRS2603 is valuable for research applications involving the modulation of purinergic signaling and the study of various physiological processes and disease mechanisms associated with P2Y receptor activity. -
P2Y1 Receptor Antagonist
MRS2496 is a selective antagonist of the P2Y1 receptor, exhibiting an IC50 value of 1.5 μM. This compound effectively demonstrates antiplatelet aggregation activity, making it a valuable tool in the study of antiplatelet mechanisms. MRS2496 is applicable in research focused on blood-related diseases, offering insights into therapeutic strategies for conditions involving platelet function. -
P2Y14 Receptor Agonist
UDP-GlcNAc serves as a full agonist of the P2Y14 receptor, a key mediator in various cellular signaling pathways. It plays a crucial role in inhibiting adenosine 3',5'-monophosphate (cAMP) formation, providing insight into metabolic processes and receptor signaling. This compound is particularly valuable in research related to bacterial infections and the study of peptidoglycan biosynthesis. -
Purinergic P2Y Receptor Activator
P1,P2-Diuridine-5'-diphosphate (Up2U) is a symmetrical dinucleoside polyphosphate that acts as a purinergic P2Y receptor activator. This compound plays a significant role in modulating cellular responses by activating purinergic signaling pathways. It is of particular interest in research areas involving neurotransmission, cellular signaling, and immune responses. P1,P2-Diuridine-5'-diphosphate can be utilized to explore the functional roles of P2Y receptors in various biological systems. -
P2Y1 Antagonist
Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a selective antagonist of the P2Y1 receptor, exhibiting no activity against P2Y2, P2Y4, or P2Y6 receptors. This compound effectively inhibits ADP-induced platelet aggregation, as well as ADP-mediated shape changes and Ca2+ elevations in platelets, while not affecting ADP's inhibition of stimulated adenylate cyclase. Additionally, it serves as a co-substrate for the sulfonation of glycans and is valuable in Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays for transferring sulfonate groups. -
P2Y6 Receptor Agonist
Uridine 5'-O-thiodiphosphate (UDP-β-S) is a stable analog of uridine diphosphate that selectively acts as an agonist for the P2Y6 receptor. This compound exhibits enhanced metabolic stability, making it valuable for investigating signaling pathways related to cardiovascular diseases. Its application in research provides insights into P2Y6 receptor-mediated processes, contributing to the understanding of cellular responses and potential therapeutic targets. -
P2Y Purinergic Receptor Agonist
2-Methylthio-ATP (2-MeS-ATP) is an agonist of the P2Y purinergic receptor, specifically designed for adenosine nucleotide modulation. This compound demonstrates key biological activity by inhibiting the release of inflammatory mediators from macrophages in response to lipopolysaccharide (LPS) stimulation. 2-MeS-ATP is a valuable tool for research into endotoxin shock and various inflammatory disorders, providing insights into purinergic signaling and its therapeutic potential. -
P2Y1 Antagonist
Adenosine 3'-phosphate 5'-phosphosulfate lithium is a selective antagonist of the P2Y1 receptor, exhibiting no activity against P2Y2, P2Y4, or P2Y6 receptors. It effectively inhibits ADP-induced platelet aggregation, as well as ADP's ability to induce shape change and Ca2+ mobilization in platelets, without affecting ADP-stimulated adenylate cyclase activity. Furthermore, this compound acts as a co-substrate for glycan sulfonation and can be utilized in Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays to facilitate the transfer of sulfonate groups. -
P2Y2 Agonist
2-Thio-UTP is a selective P2Y2 agonist exhibiting an EC50 value of 50 nM. It has demonstrated the ability to reduce pro-fibrotic gene expression and protein levels of α-smooth muscle actin. This reagent is valuable for research applications related to calcific aortic valve stenosis (CAVS) and other fibrotic disorders. -
P2Y14 receptor agonist
5'-UMPS (Uridine-5'-O-monophosphorothioate) acts as an agonist of the P2Y14 receptor. This compound has been shown to slightly induce growth in HeLa cells, highlighting its potential role in cellular proliferation studies. As a valuable tool in pharmacological research, 5'-UMPS may contribute to the understanding of purinergic signaling pathways and their biological implications. -
P2Y Receptor Antagonist
BX 667 is a selective reversible antagonist of the P2Y12 receptor, which plays a crucial role in platelet activation and aggregation. By inhibiting this receptor, BX 667 effectively attenuates thrombosis, making it a valuable tool for research into cardiovascular diseases and thrombotic disorders. Its oral bioactivity allows for convenient application in various in vivo studies related to platelet function and vascular health. -
P2Y1 receptor Antagonist
Sp-ATPαS is a competitive antagonist of the P2Y1 receptor, primarily affecting ATP-binding proteins. It effectively inhibits calcium signaling induced by ADP and demonstrates greater metabolic stability than ATP. This reagent is valuable for exploring binding interactions of metals and nucleotides in various enzymatic reactions, making it a useful tool in biochemical studies and receptor function analysis. -
P2Y1 Receptor Antagonist
MRS2298 is a potent acyclic antagonist of the P2Y1 receptor, exhibiting a Ki of 29.6 nM. This compound effectively inhibits ADP-induced platelet aggregation with an IC50 of 62.8 nM and significantly diminishes Ca2+ mobilization in platelets, presenting an IC50 of 810 nM. MRS2298 serves as a valuable tool for investigating platelet function and the role of purinergic signaling in cardiovascular research. -
P2Y2 Receptor Agonist
4-Thiouridine 5′-triphosphate tetrasodium is a potent agonist of the P2Y2 and P2Y4 receptors, exhibiting EC50 values of 35 nM and 350 nM, respectively. This UTP analog is suitable for various research applications, including cross-linking experiments and transcriptional complex labeling studies, making it a valuable tool for investigating purinergic signaling pathways. -
Acidic Dye
Acid Blue 129 is an acidic dye with a selective antagonistic effect on the P2Y receptor in guinea pig taenia coli, demonstrating its utility in biological research related to purinergic signaling. This compound does not interact with the P2X receptor in rat vas deferens, highlighting its specificity. Additionally, Acid Blue 129 is suitable for dyeing various materials, including cotton, wool, silk, nylon, paper, and leather, making it versatile for both scientific and industrial applications. -
P2Y12 Antagonist
Elinogrel potassium is a reversible, competitive antagonist of the P2Y12 receptor. This compound demonstrates significant inhibitory effects on platelet aggregation, thereby reducing thrombosis. Elinogrel potassium is utilized in research applications focused on cardiovascular diseases and thrombosis management. -
P2Y14R Agonist
MRS2905 trisodium is a selective agonist for the P2Y14 receptor, exhibiting an EC50 of 0.92 nM. This compound demonstrates a lack of activity at the UDP-activated P2Y6 receptor and other P2Y receptor subtypes. MRS2905 trisodium is a valuable tool for researchers studying purinergic signaling and its implications in various biological processes and disease states. -
P2Y Receptor
Meseclazone is an inhibitor of the P2Y receptor, demonstrating significant potency in the inhibition of secondary phase ADP-induced platelet aggregation. This compound exhibits anti-inflammatory, analgesic, and antipyretic properties, making it a valuable tool for research into thrombotic disorders and the broader mechanisms of inflammation and pain modulation. -
mAChR Antagonist
DAU 5884 is a selective antagonist of muscarinic acetylcholine receptors (mAChRs), with particular potency towards the M1 receptor subtype while exhibiting discrimination between M4 and M2 subtypes. This compound demonstrates significant biological activity in modulating signaling pathways associated with mAChR, making it a valuable tool for research in neuropharmacology and potential therapeutic applications in disorders related to cholinergic signaling. Functional assays and radioligand binding studies characterize its subtype specificity and efficacy. -
mAChR Agonist
KTX-005 is a selective agonist of the muscarinic acetylcholine receptor (mAChR), which modulates the signaling pathways associated with acetylcholine neurotransmission. This compound is primarily utilized in research focused on neuropsychiatric disorders, specifically schizophrenia. KTX-005's effects on mAChR activity make it a valuable tool for studying synaptic transmission and receptor dynamics in neurological contexts. -
mAChR Regulator
Dimethyl-W84 dibromide is a modulator of M2 muscarinic acetylcholine receptors. This compound exhibits significant regulatory activity on mAChRs, making it a valuable tool in the study of nervous system functions and disorders. Its application in research can help elucidate the role of acetylcholine signaling in various neurological conditions. -
mAChR Control
Tolterodine dimer acts as a muscarinic acetylcholine receptor (mAChR) antagonist. It serves as an impurity of Tolterodine, a compound known for its potent activity against mAChRs. This reagent is primarily utilized in research applications aimed at investigating cholinergic signaling pathways and evaluating potential therapeutic strategies for bladder control and related disorders. -
mAChR Agonist
NNC 11-1607 is a selective agonist for the M1 and M4 subtypes of muscarinic acetylcholine receptors (mAChR). It effectively inhibits Forskolin-stimulated cAMP accumulation in human M2 and M4 mAChR-expressing Chinese hamster ovary cells. This compound shows potential for investigating central nervous system disorders, including Alzheimer’s disease and schizophrenia, making it a valuable tool for related research applications. -
mAChR Antagonist
Atropine oxide hydrochloride is a competitive antagonist of muscarinic acetylcholine receptors, including M1, M2, M3, M4, and M5. It demonstrates key biological activity in antagonizing acetylcholine's effects, making it valuable in research focused on neurotransmission and receptor signaling. This reagent is particularly significant for studies involving the therapeutic applications in specific nerve agent and pesticide poisonings. -
Stable Isotope
Rac-Fesoterodine-d14 fumarate is a stable isotope-labeled version of the racemic muscarinic receptor antagonist Fesoterodine. It exhibits competitive inhibition across multiple mAChR subtypes, with pKivalues of 8.0, 7.7, 7.4, 7.3, and 7.5 for M1, M2, M3, M4, and M5 receptors, respectively. This compound is primarily utilized in research applications focusing on the pharmacological characterization and monitoring of overactive bladder treatments. -
mAChR
Revefenacin impurity 4 is an intermediate compound associated with Revefenacin, targeting the human M3 muscarinic acetylcholine receptor. This impurity demonstrates significant binding affinity with a Ki value of 55 nM, highlighting its potential as a pharmacological agent. It is useful for research applications involving muscarinic receptor modulation and the study of cholinergic signaling pathways. -
mAChR Control
(Rac)-5-Carboxy tolterodine is an inactive metabolite of the muscarinic acetylcholine receptor antagonist Tolterodine. It serves as a valuable control in studies involving muscarinic receptors, particularly in the context of acetylcholine modulation. This compound is useful for researchers investigating the pharmacokinetics and metabolic pathways of Tolterodine and related drugs. -
mAChR Antagonist
5-Hydroxymethyl tolterodine formate is a potent antagonist of muscarinic acetylcholine receptors (mAChR). This active metabolite, derived from tolterodine and fesoterodine through the action of CYP2D6 and plasma esterases respectively, has significant implications in the study of urinary disorders. Researchers can utilize 5-Hydroxymethyl tolterodine formate in pharmacological investigations of cholinergic signaling and its effects on smooth muscle activity, contributing to the understanding of treatment options for overactive bladder and related conditions. -
mAChR Antagonist
Alvameline maleate is a muscarinic acetylcholine receptor (mAChR) antagonist with selective activity at the M2 and M3 subtypes, while acting as a partial agonist for the M1 subtype. This compound has demonstrated the ability to competitively inhibit contractions in human detrusor muscle induced by ammonium chloride and electrical field stimulation, highlighting its potential for applications in bladder function regulation. Furthermore, alvameline maleate has shown promise in enhancing cognitive function following traumatic brain injury in rodent models, making it a valuable tool for research in both urology and neuropharmacology. -
mAChR Antagonist
Temiverine hydrochloride is a mAChR antagonist exhibiting anticholinergic activity. This compound is also a versatile click chemistry reagent, featuring an alkyne group that enables the copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its applications extend to chemical biology, facilitating the development of novel therapeutics and biochemical probes. -
mAChR Antagonist
Ambutonium bromide is a selective antagonist of the muscarinic acetylcholine receptors (mAChRs). By inhibiting the action of acetylcholine, it plays a significant role in modulating cholinergic signaling pathways. This compound is primarily utilized in research applications aimed at studying the effects of mAChR inhibition in various physiological and pathological contexts. -
mAChR Agonist
ENS-163 phosphate is a selective muscarinic acetylcholine receptor (mAChR) M1 agonist. It exhibits significant biological activity by modulating M1 receptor signaling pathways, which are implicated in cognitive processes. This compound is valuable for research applications related to neuropsychological disorders and the exploration of potential therapeutic targets in Alzheimer's disease and other cognitive impairments. -
mAChR Antagonist
Rispenzepine is an antimuscarinic compound that selectively antagonizes M1 and M3 muscarinic acetylcholine receptors (mAChRs). This compound exhibits significant biological activity in modulating cholinergic signaling pathways, making it valuable for research on neurological disorders and other conditions influenced by mAChR activity. Its specific receptor selectivity positions Rispenzepine as a useful tool in studies focused on receptor function and the development of therapeutic interventions. -
mAChR Agonist
Muscarine tosylate is a potent agonist of the muscarinic acetylcholine receptors (mAChRs). This compound selectively stimulates the parasympathetic nervous system, leading to various physiological effects. Muscarine tosylate is widely utilized in research applications focusing on neuropharmacology and the modulation of cholinergic signaling pathways. -
Metabolite of Oxybutynin
N-Desethyloxybutynin hydrochloride is an active metabolite of Oxybutynin, primarily targeting muscarinic acetylcholine receptors (mAChRs). This compound demonstrates significant binding affinity in isolated human bladder and parotid gland tissues, with pKi values of 8.2 and 8.7, respectively. It is useful in research exploring bladder function, salivary secretion, and the pharmacological effects of anticholinergic agents. -
Stable Isotope
(R)-Hydroxytolterodine-d14 is a deuterated form of Desfesoterodine, a selective antagonist of muscarinic acetylcholine receptors (mAChRs). This compound exhibits high potency, with a KB value of 0.84 nM and a pA2 of 9.14. As a significant metabolite of Tolterodine and Fesoterodine, it has demonstrated efficacy in models of cerebral infarction-induced detrusor overactivity in rats, making it valuable for research in urology and neurology. -
mAChR Antagonist
WIN 62,577 is a selective antagonist of muscarinic acetylcholine receptors (mAChRs), specifically targeting M1 to M4 subtypes. This compound acts as an allosteric enhancer of acetylcholine affinity at the M3 receptor, making it a valuable tool for studying cholinergic signaling. Its unique properties allow for exploration of mAChR-related pathways and their implications in various physiological and pathological conditions. Suitable for research applications in neurobiology and pharmacology, WIN 62,577 facilitates investigations into receptor functions and potential therapeutic targets. -
mAChR Antagonist
Cyclodrine hydrochloride is a potent antagonist of muscarinic acetylcholine receptors (mAChRs). It is primarily utilized in research to investigate cholinergic signaling pathways and the role of mAChR in various physiological and pathological processes. This compound may aid in the exploration of potential therapeutic targets for disorders influenced by cholinergic activity. -
mAChR Agonist
CDD0102 is a potent agonist of the M1 muscarinic acetylcholine receptor (mAChR). It demonstrates significant biological activity in promoting M1 receptor signaling pathways, making it valuable for research into neurobiology and cognitive function. CDD0102 is essential for studies investigating the role of muscarinic receptors in various physiological and pathological processes.
